
    
      The investigators will verify patients with cardiac heart failure (CHF) and preserved
      systolic function and each patient must have all clinical evaluation through basal
      measurements of blood pressure, heart rate, biochemical tests, and color Doppler
      echocardiographic parameters for at least 12 years.

      The investigators will evaluate the effects of an aldosterone antagonist as canrenone
      compared to a group without canrenone and the investogators will verify how many patients
      reported cardiovascular mortality or will survive.
    
  